Workflow
Gyre Therapeutics(GYRE) - 2021 Q1 - Quarterly Report
GYREGyre Therapeutics(GYRE)2021-05-07 01:00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Securities registered or to be registered pursuant to Section 12(b) of the Act. Commission file number: 000-51173 | Title of each class Trading Symbol(s) | ...